Incyte Says Early Data Points To Promise For Once-Monthly Preventive Treatment For Inherited Blood Disorder

기사 요약

Incyte reports Phase 1/2 latarcibart data showing lower bleeding rates and favorable safety in patients with von Willebrand disease.